Division

BrightPoint (BP) LLC Awarded Federal Bureau of Investigation (FBI) Criminal Justice Information Services (CJIS) Contract

Retrieved on: 
Tuesday, March 12, 2024
I3, SoS, BP, Information technology, Intelligence, CJIS, Research, State bureau of investigation, BrightPoint, Safety, FBI, Division, Engineering, Criminal Justice Information Services, Private investigator

WASHINGTON, March 12, 2024 /PRNewswire-PRWeb/ -- BrightPoint (BP) LLC, an 8(a) joint venture between Buchanan & Edwards (BE) and i3, has been awarded a contract for $12 million with the Federal Bureau of Investigation (FBI). This significant contract entrusts BP with the responsibility of providing Subject Matter Experts to support the FBI's Criminal Justice Information Services (CJIS) Division.

Key Points: 
  • A $12M T&M FBI contract has been awarded to BrightPoint LLC, a joint venture between Buchanan & Edwards and i3, to support the Criminal Justice Information Services (CJIS) Division.
  • WASHINGTON, March 12, 2024 /PRNewswire-PRWeb/ -- BrightPoint (BP) LLC, an 8(a) joint venture between Buchanan & Edwards (BE) and i3, has been awarded a contract for $12 million with the Federal Bureau of Investigation (FBI).
  • This significant contract entrusts BP with the responsibility of providing Subject Matter Experts to support the FBI's Criminal Justice Information Services (CJIS) Division.
  • This contract reinforces our dedication to innovation and collaboration as we focus on the development, engineering, and architecture of systems to equip law enforcement, national security, and intelligence partners with essential criminal justice information.

AI Model Makes Hospital Notes Patient-Friendly

Retrieved on: 
Monday, March 11, 2024
JAMA Network Open, Informatics, Abbreviation, OpenAI, Learning, NYU Langone Health, Associate, Physician, Patient, Intuition, Internet, Artificial intelligence, AI, NYU, MD, Hospital medicine, Thought, MCIT, Translation, Population health, Division, Privacy, Multimedia, Nursing, Engineering, Medical device

The research focuses on discharge notes written by doctors to capture patient's health status in the medical record as they are discharged from the hospital.

Key Points: 
  • The research focuses on discharge notes written by doctors to capture patient's health status in the medical record as they are discharged from the hospital.
  • Specifically, running discharge notes through generative AI dropped the reports from an eleventh-grade reading level on average to a sixth grade level, the gold standard for patient education materials.
  • They also found that just 56% of notes created by AI were entirely complete.
  • Feldman notes that generative AI tools are sensitive, and asking a question of the tool in two subtly different ways may yield divergent answers.

FTC Announces Tentative Agenda for March 21 Open Commission Meeting

Retrieved on: 
Tuesday, April 2, 2024
TSR, Comment, Webcast, Social media, News, Marketing, Commission, Fraud, Division, Federal Trade Commission, FTC

Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, March 21, 2024.

Key Points: 
  • Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, March 21, 2024.
  • The open meeting will commence at 11am ET and will begin with time for members of the public to address the Commission.
  • Members of the public must sign up for an opportunity to address the Commission virtually at the March 21 event.
  • Follow the FTC on social media, read our blogs and subscribe to press releases for the latest FTC news and resources.

FTC Announces Tentative Agenda for March 21 Open Commission Meeting

Retrieved on: 
Tuesday, April 2, 2024
TSR, Comment, Webcast, Social media, News, Marketing, Commission, Fraud, Division, Federal Trade Commission, FTC

Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, March 21, 2024.

Key Points: 
  • Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, March 21, 2024.
  • The open meeting will commence at 11am ET and will begin with time for members of the public to address the Commission.
  • Members of the public must sign up for an opportunity to address the Commission virtually at the March 21 event.
  • Follow the FTC on social media, read our blogs and subscribe to press releases for the latest FTC news and resources.

SEC Charges Lordstown Motors with Misleading Investors about Company's Flagship Electric Vehicle

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Division, Proxy, Bankruptcy, Associate, Security (finance), Bank statement, CSH, Renewable energy

Company's former auditor charged with violating auditor independence standards

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - February 29, 2024) - The Securities and Exchange Commission today charged Lordstown Motors Corp. with misleading investors about the sales prospects of Lordstown’s flagship electric pickup truck, the Endurance.
  • Lordstown, which filed for bankruptcy in 2023, went public by merging with a special purpose acquisition company (SPAC) in 2020.
  • The SEC also instituted a related, settled administrative proceeding against Lordstown’s former auditor, Clark Schaefer Hackett and Co. (CSH).
  • CSH provided certain non-audit services, including bookkeeping and financial statement services, to Lordstown during CSH’s audit of the company’s financial statements when it was a private entity.

SEC Announces Departure of William Birdthistle; Natasha Vij Greiner Named Director of the Division of Investment Management

Retrieved on: 
Wednesday, February 28, 2024
Investment, Award, Division, Psychology, Home Office, Assistant, University, Investment management, Columbus School of Law, Form, Harvard Law School, Conference, James Madison University, Faculty, History, Harvard Law Review, Associate, Chicago-Kent College of Law, Catholic University of America, Duke University, Policy, Security (finance), Catholic higher education, Commission, Rope, Ropes & Gray, Financial adviser

Natasha Vij Greiner, currently the Deputy Director of the Division of Examinations, will be named Director of the Division of Investment Management upon Mr. Birdthistle’s departure.

Key Points: 
  • Natasha Vij Greiner, currently the Deputy Director of the Division of Examinations, will be named Director of the Division of Investment Management upon Mr. Birdthistle’s departure.
  • The Division oversees regulatory policy for investment advisers and investment companies, including mutual funds and other investment products and services relied upon by retail investors.
  • “I am grateful to William for his service to the SEC and to the investing public,” said SEC Chair Gary Gensler.
  • “I am excited for the opportunity to lead the exceptional staff in the Division of Investment Management,” said Ms. Greiner.

Bio-Path Holdings Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024
Division, Research, AML, University, Clinical trial, Chronic lymphocytic leukemia, CLL, Holding, MD Anderson Cancer Center, Patient, D.O, Lymphoma, KOL, Pharmaceutical industry

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Key Points: 
  • “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
  • As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
  • Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
  • ET to review these full-year 2023 financial results and to provide a general update on the Company.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024
SAN, Neoplasm, Division, Research fellow, Immunotherapy, Colorectal cancer, Gastrointestinal cancer, Drug development, Mentorship, Clinical research, Pembrolizumab, CRC, MSS, National Cancer Institute, FACP, Preventive healthcare, Gene expression, NCCN, USC, Associate, Patient, Harvard Medical School, Oncology, George Washington University, Cancer, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Retrieved on: 
Thursday, March 7, 2024
Master of Science, Breast cancer, BCT, Division, CMO, Doctor of Philosophy, MD, University, Quality of life, TSX, Letter, Vaccine, Breast, MD Anderson Cancer Center, Cancer, Therapy, Associate professor, Patient, Survival, Disease, Prostate cancer, Pharmaceutical industry

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell

Key Points: 
  • Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
    PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
  • “We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO.
  • “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
    “Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO.
  • “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”

Kamada Issues 2024 CEO Letter to Shareholders

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, KMDA, CMV, Hospital, Division, EMA, CSL Behring, Letter, Physician, Critical care, FDA, Technology transfer, Food, Growth, FEV1, AAT, Immunoglobulin G, Safety, University, European Medicines Agency, Food and Drug Administration, Pan American Health Organization, Patient, Plasma, Research, Partnership, Pharmaceutical industry

The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.

Key Points: 
  • The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
  • Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year.
  • These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk.
  • On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize.